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Effect of Therapeutic Integrin (CD11a) Blockade
with Efalizumab on Immune Responses to Model
Antigens in Humans: Results of a Randomized,
Single Blind Study
James G. Krueger1, Hans D. Ochs2, Piyush Patel3, Ellen Gilkerson4, Emma Guttman-Yassky1
and Wolfgang Dummer4
Efalizumab is a humanized monoclonal CD11a antibody approved for treatment of psoriasis. Its immunomodu-
latory effects led us study how immune responses are modified and the possible consequences for vaccinations in
clinical practice. This was a randomized, single-blind, placebo-controlled, parallel-group study of 12 weeks of
subcutaneous efalizumab treatment of patients with moderate psoriasis. Bacteriophage fX174 was used as a model
neoantigen to assess T-cell-dependent humoral immunity. Tetanus booster vaccine, pneumococcal vaccine, and
intracutaneous skin tests were administered to further evaluate humoral and cellular immune responses. During
efalizumab treatment, both primary and secondary antibody responses to fX174, including IgM/IgG isotype switch,
were reduced. There appeared to be naı¨ve T-cell anergy to a neoantigen (fX174) during active CD11a blockade,
without tolerance to the antigen after efalizumab withdrawal. Secondary humoral immune responses to tetanus
booster during treatment were reduced, but antibody titer increases led to protective levels. Responses to
pneumococcal vaccination 6 weeks after withdrawal from efalizumab were not affected. Cellular immune
responses to intracutaneous recall antigens were reduced during treatment and returned to pretreatment
conditions after withdrawal. These results expand our knowledge of how immune responses are modulated in
humans by CD11a blockade and have implications for vaccinations of patients treated with this agent.
Journal of Investigative Dermatology (2008) 128, 2615–2624; doi:10.1038/jid.2008.98; published online 22 May 2008
INTRODUCTION
The initial step in the activation of an immune response is
presentation of an antigen-derived peptide bound to major
histocompatibility complex on antigen-presenting cells to
T cells. Interaction of costimulatory molecules expressed by
antigen-presenting cells, such as CD80 (B7.1), CD86 (B7.2),
CD40, or intercellular adhesion molecule-1, with their
ligands, CD28, CD40L, or lymphocyte function-associated
antigen-1 (LFA-1), is required for full T-cell activation.
Efalizumab, a humanized mAb against CD11a, targets the
a-chain subunit of the LFA-1 molecule and prevents its
interaction with intercellular adhesion molecule-1. Efalizu-
mab is approved in many countries for treatment of
moderate-to-severe psoriasis, with safety and efficacy estab-
lished in large phase-III trials (Gordon et al., 2003; Lebwohl
et al., 2003). It is important to understand how therapeutic
blockade of LFA-1 with efalizumab impacts the immune
processes of autoimmune inflammation as well as normal,
protective immune responses to foreign antigens.
In the initial phases of immune responses, binding of
intercellular adhesion molecule-1 to LFA-1 plays an important
role in forming the so-called immunological synapse between
an activated antigen-presenting cell and a T cell, providing
stabilization for signal exchange to achieve T-cell or B-cell
activation, proliferation, and migration. LFA-1 blockade
inhibits T-cell activation and natural killer cell cytolysis
in vitro (Krensky et al., 1983; Dustin and Springer, 1988) and
T-cell-dependent B-cell proliferation and antibody production
(Fischer et al., 1986; Benjamin et al., 1988), as well as target T-
cell lysis and lymphocyte proliferation (Tanaka et al., 1995). In
addition to its function as a coactivator, LFA-1 blockade leads
to reduced adhesion of T cells to the vascular endothelium
(Dustin and Springer, 1988), resulting in reduced trafficking
and homing of T cells into tissues (Hamann et al., 1988;
Issekutz, 1992). In preclinical studies with rodents, antibodies
targeting CD11a-induced tolerance (anergy) toward donor
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antigens after bone marrow transplantation (Cavazzana-Calvo
et al., 1995) blocked the induction of experimental auto-
immune encephalitis (Gordon et al., 1995), reduced the
incidence of corneal graft rejection (He et al., 1994), and
prolonged survival in various models of tissue and solid-organ
allograft (Isobe et al., 1992; Nakakura et al., 1993; Talento
et al., 1993; Dedrick et al., 2002). Although these anti-
inflammatory and tolerance-inducing effects are desirable in
the treatment of autoimmune diseases, they could also affect
primary and secondary immune responses to foreign antigens
and vaccinations.
In this study, we used several vaccines and model antigens
to assess immune responses to proteins and polysaccharides.
In general, acquired immune responses to polysaccharide
antigens are dependent on intact B-cell function, whereas a
full response to protein-based antigens also requires intact
T-cell function. Because in theory primary presentation of a
new protein antigen under certain circumstances, such as
CD80/CD86 or anti-CD11a blockade, might induce perma-
nent non-responsiveness (tolerance), a primary immune
response should not be assessed with a human pathogen.
Hence, the non-pathogenic, virus-like bacteriophage fX174
served as the protein neoantigen during and after efalizumab
treatment. In normal individuals, fX174 triggers develop-
ment of IgM antibodies to the first injection and T-cell-
dependent switching to IgG antibodies usually starts with the
second injection of fX174. In patients with inherited immune
deficiency diseases, for example, severe combined immune
deficiency, leukocyte adhesion deficiency disease (bearing a
CD18 mutation), or X-linked agammaglobulinemia (as well
as a number of other diseases), IgM or IgG antibody responses
to fX174 are suppressed or absent (Ochs et al., 1993; Price
et al., 1994). Therapeutic immune modulators such as
CTLA4-Ig, which blocks T-cell costimulation (Abrams et al.,
1999), or rituximab, which depletes CD20þ B-cells (Beard-
en et al., 2005), have been shown to suppress IgG antibody
responses to fX174, with rituximab also suppressing the IgM
response to this antigen (Bearden et al., 2005). Hence,
various aspects of immune function, such as antigen
recognition, amplification, immunological memory, and
isotype switching, can be well quantified in the fX174
system, whereas extensive prior testing of immune-altered
individuals gives the ability to interpret outcomes within the
context of the human immune system and immune defi-
ciency (Gordon et al., 2003; Lebwohl et al., 2003). Using the
fX174 antigen, we assessed the immunological recognition
of a neoantigen by B cells and T cells during treatment, and
addressed the questions, whether tolerance beyond treatment
was induced in T cells via therapeutic LFA-1 blockade upon
first antigen encounter. This study, with its wide spectrum of
antigens used, provides key data on the mechanism of action
of efalizumab in humans, as well as important clinical
guidance for handling immunizations during its use.
RESULTS
Patient disposition
Sixty-six patients with moderate plaque psoriasis were
enrolled. Of the 66 patients enrolled and randomized, 62
(94%) completed the 12-week treatment period and 61 (92%)
completed the 14-week follow-up (Figure 1). Six patients
randomized to group B unintentionally received active
fX174 vaccine during the efalizumab treatment period; in
all analyses, these patients are included as treated in group A.
Thus, 28 patients were included in group A, 16 in group B,
and 22 in group C. Demographic and baseline psoriasis
characteristics were generally comparable across treatment
groups (Table 1). The study design is shown in Figure 2a.
Groups A and B received Efalizumab (1 mg/kg) weekly for 12
weeks, Group C received placebo treatment. For immuniza-
tions, Groups A and C received the experimental antigen
fX174 twice during the first 12 weeks and twice after study
drug discontinuation. Group B received vehicle fX174 twice
during the treatment period and fX174 twice after the
treatment period. Tetanus booster vaccinations, intracuta-
neous skin tests and pneumococcal vaccines were adminis-
tered as shown in the study design (Figure 2a).
Pharmacodynamic effect of efalizumab on CD11a-binding
sites and expression
During efalizumab treatment, all CD11a-binding sites on
circulating B and T lymphocytes were occupied 100% by
efalizumab (data not shown). In addition, the number of
remaining CD11a molecules on the surface of T cells was
reduced by approximately 80% for both groups A and B (and
this reduction or down-modulation was maximal by day 35),
as assessed with a CD11a antibody binding to a distinct
epitope from efalizumb (Figure 2b). Efalizumab is eliminated
from the body approximately 7 weeks after the last dose
(follow-up day 42) (Gottlieb et al., 2000). By day 42 of the
efalizumab wash-out follow-up period, the number of CD11a
molecules on the surface of T cell returned to normal (Figure
2b) and no residual efalizumab binding could be detected
(data not shown).
As expected, CD11a expression remained close to base-
line throughout the study for group C (Figure 2b). During
active efalizumab treatment, CD11a expression on B cells
was downregulated by approximately 35–40% of baseline
(Figure 2c).
Antibody responses to /X174
During treatment, antibody responses to fX174, measured as
phage-neutralizing activity and expressed as K-value (Kv),
were determined at immunization and 2 and 4 weeks
following immunization (Figure 3a). The geometric mean
(GM) Kv was approximately 10-fold lower in the efalizumab-
treated group A, compared with that in placebo-treated group
C, and was also below the lower 95% confidence interval (CI)
determined for group C. However, substantial antibody
responses occurred in efalizumab-treated patients (group A)
and the resulting antibody titer was sufficient to neutralize
fX174 after the second and subsequent immunizations (no
circulating infectious phage was present in the peripheral
blood 15 minutes after these infusions). These results indicate
B cells recognize fX174 antigen during efalizumab treatment
and that recall responses and immune amplification are
largely intact. Antibody responses to immunizations were
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further characterized by determining the isotype switching
from IgM to IgG, which is dependent on T-cell recognition of
a protein-based antigen. At 2 weeks post secondary
immunization, 0.13% of the antibody was of the IgG isotype
in groups A and B versus 25% in group C (Figure 3b). Hence,
anti-fX174 antibodies failed to isotype switch during
efalizumab treatment, indicating a likely state of T-cell
anergy to fX174. However, when boosted with phage
(immunizations 3 and 4) after efalizumab discontinuation,
both group A and group B patients had an increase in
antibody titer with 8 and 15% IgG antibody, respectively, at 2
weeks and 11 and 20% at 4 weeks after the fourth
immunization. This indicates T-cell responsiveness to
fX174 upon efalizumab wash out, such that permanent
T-cell anergy and tolerance to this phage were not induced,
although magnitude of the antibody response was still
somewhat reduced.
Immunization with fX174 after discontinuation of efali-
zumab in patients who had received phage vehicle during
efalizumab treatment (group B) resulted in an antibody
response slightly lower in magnitude compared with the first
two immunizations in group C patients (Figure 3a), suggesting
some residual efalizumab effect at follow-up day 42. The
reduced response was independent of CD11a expression
(Figure 2b and c) or saturation of CD11a-binding sites on
T cells or B cells.
Antibody responses to tetanus immunization
Four weeks after tetanus booster immunization given on
treatment day 35, efalizumab-treated patients (groups A and B)
Assessed for eligibility (n=98) 
Is it randomized? 
Yes 
 Allocation
Group A Group B Group C  
Allocated to intervention 
(n=22) 
Received allocated 
intervention (n=21) 
Did not receive allocated 
intervention (n=1) 
Reasons       Personal reason
Allocated to intervention 
(n=22) 
Received allocated intervention 
(n=20)  
Did not receive allocated 
intervention (n=2)  
Reasons   1 patient
discontinued treatment because 
of an adverse event, the other 
because of personal reasons    
Allocated to intervention (n=22) 
Received allocated intervention 
(n=21) 
Did not receive allocated 
intervention (n=1)  
Reasons Personal reason 
Follow -Up
Lost to follow-up (n=0) 
Discontinued intervention 
(n=0)
Lost to follow-up (n=1) 
Discontinued intervention 
(n=1)  
Reasons   
lost to follow-up because of 
personal decision (not because 
of adverse events)  
  The patient was
Lost to follow-up (n=0) 
Discontinued intervention (n=0)
Analysis
Analyzed (n=22) 
Excluded from analysis (n=1)  
Reasons  Stopped 
treatment
Analyzed (n=19) 
Excluded from analysis (n=3) 
Reasons   
  No treatment or 
follow-up
Analyzed (n=21) 
Excluded from analysis (n=1) 
Reasons   
  Stopped treatment 
Excluded (n=32) 
Not meeting 
inclusion criteria 
(n=32)
Enrollment n=66
Figure 1. The CONSORT flowchart.
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showed an approximately threefold increase in the levels
of anti-tetanus toxoid IgG antibody (Figure 4a). The increase
in placebo-treated group C was approximately 10-fold. At
screening, 31 of 43 (72%) efalizumab-treated patients and 17
of 22 (77%) placebo-treated patients had anti-tetanus toxoid
IgG levels X0.5 IU ml1; 4 weeks after tetanus immuniza-
tion, 40 of 42 (95%) efalizumab-treated patients and all of 22
(100%) placebo-treated recipients had positive anti-tetanus
toxoid IgG levels (Figure 4b). In addition, 35 of 42 (83%) of
efalizumab-treated patients and 21 of 22 (95%) of placebo-
treated recipients demonstrated an increase in anti-tetanus
toxoid IgG levels of X0.5 IU ml1 above preimmunization
levels at 4 weeks after tetanus immunization.
Antibody responses to pneumococcal polysaccharides
The assay used in this study detects IgG antibodies against 12
of the 23 antigens included in Pneumovaxs. At baseline,
before immunization patients in all groups generally had
antibody titers X1.4 mg ml1 IgG to at least some pneumo-
coccal antigens (typically one to three strains). The increase
in the number of positive titers after vaccination to any of the
12 measured pneumococcal antigens was determined and
compared in the efalizumab- and placebo-treated groups.
The percentage of patients who converted antibody levels
to at least one (X1) and X2, X3, and X6 additional
pneumococcal strains was generally similar between the
efalizumab and placebo groups (Figure 5). Increases in
median antibody levels after immunization were also similar
between groups (data not shown).
Skin test responses to recall antigens
At screening, approximately 80% of all patients had at least
one positive skin test (Figure 6). Skin test results at day 35
were positive to Candida albicans in 57 and 91% of
efalizumab- and placebo-treated patients, respectively
(P¼0.009). By follow-up day 77, skin tests were similar to
baseline in all the groups (Figure 6a). At screening, the
percentage of patients with a positive tetanus toxoid skin test
reaction was low for all the groups: 52% for patients to be
treated with efalizumab versus 36% for patients to be treated
with placebo (Figure 6b). The proportion of efalizumab-
treated patients with positive skin test reactions to tetanus
toxoid skin testing was reduced compared with placebo-
treated patients at day 35 (24 vs 41%) and increased only
slightly by follow-up day 77 (30 vs 38%).
Adverse events experienced during the study
The most frequent adverse events were infection (32% for
placebo-treated patients versus 16% for efalizumab-treated
patients). One serious adverse event occurred in a placebo-
treated patient. The most frequent adverse events for
efalizumab-treated patients were psoriasis (52%) and head-
aches (39%), mostly mild to moderate; there was one severe
exacerbation of psoriasis. No adverse events of arthritis,
hemolytic anemia, or thrombocytopenia were reported. No
adverse events were associated with immunizations.
DISCUSSION
Therapeutic intervention for autoimmune diseases seeks to
dampen pathological immune responses toward self-anti-
gens. However, in doing so, immune responses to pathogens
or vaccines might also be affected in an undesired manner.
There is little information on how novel biological treatments
impact immune responses, for example, to vaccines, despite
this being an important health issue. Moreover, because
animal models demonstrated tolerance induction through
blockade of costimulatory molecules on T cells and CD11a
specifically (Benjamin et al., 1988; Cavazzana-Calvo et al.,
1995), a theoretical concern could be the induction of
sustained unresponsiveness to viral or other pathogens in
humans. Thus, thorough characterization of immune re-
sponses to antigens during and after any immunomodulatory
Table 1. Baseline demographic and psoriasis
characteristics
Characteristic
Group A
(efalizumab+
/X174) (n=28)
Group B
(efalizumab+
vehicle
immunization)
(n=16)
Group C
(placebo+
/X174) (n=22)
Age (years)
Mean (SD) 45.0 (11.6) 40.9 (12.1) 40.4 (9.9)
Median
(range)
45 (21–65) 38 (19–63) 42 (23–58)
Sex, n (%)
Men 23 (82.1) 9 (56.3) 13 (59.1)
Women 5 (17.9) 7 (43.8) 9 (40.9)
Race/ethnicity, n (%)
White 25 (89.3) 13 (81.3) 18 (81.8)
Black 0 2 (12.5) 0
Asian/
Pacific
Islander
1 (3.6) 1 (6.3) 2 (9.1)
Hispanic 1 (3.6) 0 0
Other 1 (3.6) 0 2 (9.1)
Duration of psoriasis (years)
Mean (SD) 15.2 (9.2) 17.5 (8.7) 14.1 (9.1)
Median
(range)
13.5 (1–32) 15.5 (4–39) 11.5 (4–39)
BSA affected (%)
Mean (SD) 11.3 (2.2) 11.7 (2.1) 11.2 (2.3)
Median
(range)
11.1 (8.0–14.5) 11.3 (8.0–14.5) 10.5 (8.0–15.0)
Prior systemic or phototherapy for psoriasis, n (%)
Yes 11 (39.3) 10 (62.5) 9 (40.9)
No 17 (60.7) 6 (37.5) 13 (59.1)
BSA, body surface area.
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treatment is of major clinical relevance. This trial used a
comprehensive set of model antigens and vaccines to
investigate humoral and cellular responses, and addressed
the question of induction of sustained unresponsiveness to a
model antigen in humans.
The results of this trial further define the effect of
efalizumab on primary and recall immune responses in
psoriasis patients treated with therapeutically relevant doses
of the CD11a antibody. In untreated control patients, the
primary B-cell response to bacteriophage fX174 generated
high levels of IgM antibodies, whereas efalizumab-treated
patients demonstrated a lower, but still substantial response
to fX174. Overall, the levels of antibody attained after the
first antigen exposure were maintained in control patients as
well as in efalizumab-treated patients. Immunological
memory to the fX174 antigen seems to be apparent in both
control and efalizumab-treated patients, suggested by further
increases in anti-fX174 antibody levels upon second, third,
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Figure 2. Study design and rationale for immunization time points. (a) The study schema: In the treatment period (day 0 through day 84 (¼ FU day 0))
patients received 1 mg kg1 week1 of efalizumab (groups A and B) or placebo (group C). All patients underwent a 14-week follow-up period (FU days 0–98).
Group A and group C (placebo) patients were immunized with fX174 twice during (days 35 and 63 of efalizumab therapy) and twice after efalizumab
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on CD3þ T lymphocytes demonstrates maximum downregulation by the time of first immunization and recovery by the time of FU immunizations.
(c) Mean CD11a expression on B cells and downregulation to approximately 40% of baseline by day 35 with recovery by FU day 42. FY, follow-up.
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and fourth injections of this bacteriophage (groups A and C).
Psoriasis patients treated with efalizumab and exposed to
fX174 during the active treatment phase (group A) showed
blockade of the IgM-to-IgG isotype switch, indicating an
impaired naı¨ve T-cell response to this protein-based neoanti-
gen. However, upon discontinuation of efalizumab and re-
expression of LFA-1 on T cells, subsequent exposure to
fX174 produced substantial levels of IgG antibodies (group A),
indicating return of T-cell helper function. Subjects treated
with efalizumab but receiving fX174 for the first time in
follow-up (group B) displayed both IgM and IgG antibody
responses. Isotype switching in both efalizumab-treated
groups was still somewhat reduced as compared with that
in control patients (group C), but reflected mostly competent
T-cell function. Hence, during active LFA-1 blockade, naı¨ve
CD4þ T cells appear to be in an anergic state, with impaired
ability to provide T-cell help to B cells, but tolerance beyond
cessation of efalizumab treatment is not induced. Finally,
immunizations with fX174 led to a degree of antibody
production (IgM or IgG) sufficient to rapidly clear circulating
fX174 15 minutes after injection. Quantitative levels of IgM
or IgG likely determine the duration and effectiveness of
immunity against this antigen.
Responses to a tetanus booster vaccination during
(a protein antigen), and to pneumococcal antigens (carbo-
hydrate antigens) after efalizumab treatment, are present,
although the magnitude of tetanus response was lower than
that in in control patients. Delayed-type hypersensitivity
responses, which are dependent on antigen presentation as
well as cellular trafficking to the skin, are both only
moderately suppressed during efalizumab treatment, which
is surprising as theoretically LFA-1 blockade could prevent
migration of memory T cells into the skin at an inflammatory
site.
The results obtained in this study revealed less impact on
immune responses than in other situations of immunomodu-
lation. Immunization data from rituximab, an anti-CD20
B-cell-depleting antibody, led to stronger ablation of anti-
body responses to fX174 (Bearden et al., 2005). Moreover, in
patients with primary or acquired T-cell immune deficiency,
reduction of antibody responses to fX174 was much stronger
than during efalizumab treatment (Ochs et al., 1971, 1993;
Pyun et al., 1989; Price et al., 1994). Finally, the relatively
rapid re-expression of CD11a on T cells after discontinuation
of efalizumab treatment suggests quick reversibility of effects.
The data reported here are consistent with those of another
recent study showing that efalizumab treatment strongly
reduced T-cell activation produced by a polyclonal stimulus
(T-cell activation by CD3 ligation), with this effect being fully
reversible upon wash out of efalizumab (Guttman-Yassky
et al., 2007). Overall, T-cell reactivity and reduced expres-
sion of T-cell-surface proteins were reduced only when
efalizumab was present at saturating levels for CD11a, and
these effects are reversed fully upon discontinuation of
treatment (Guttman-Yassky et al., 2007).
Results presented here may be considered in the clinical
management of vaccinations for psoriasis patients undergoing
treatment with efalizumab, although it is generally unclear
whether or not any result using a model vaccination antigen
can be extrapolated to other test systems or clinically used
vaccination. Moreover, the role of protective antibodies,
which can be measured relatively easily in a clinical trial
setting, versus the role of antigen-specific T-cell memory is
not fully understood. Opinions range from the view that
antibodies are primarily responsible for the control of
bacterial infections and are dispensable for the control of
most viral infections (Whitten and Oldstone, 2001), to the
view that antibodies are the only identified agents of
successful vaccine protection (Zinkernagel et al., 2001).
Thus, the fact that administration of neoantigen during
treatment led to an IgM response, but a block in IgG/IgM
isotype switch, suggests that some immunity during treatment
is likely still induced, but may not be as high and long-lasting
as a full blown response in an untreated control population.
Therefore, live vaccines are not to be recommended during
efalizumab treatment, although this study did not directly
address this situation. Since withdrawal of the immuno-
modulatory agent widely re-installed IgG isotype switch,
no detrimental long-term effect beyond drug withdrawal is
anticipated for killed vaccines. Tetanus booster immunization
during treatment led to a meaningful increase of anti-tetanus
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m: Immunization with fX174 (groups A and C) or vehicle (group B) and
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IgG and is likely to enhance immunity even during
efalizumab treatment. Finally, pneumococcal vaccinations
were not impacted at all after withdrawal from efalizumab.
These conclusions are similar to those given for other
immune modulators such as prednisone, metrotrexate,
cyclosporine A, mycophenolate mofetil, etanercept, and
others (Derkx et al., 1993; Elliott et al., 1994a, b, 1997; van
Dullemen et al., 1995; Moreland et al., 1996, 1997; Dengler
et al., 1998; Abrams et al., 1999; Mease et al., 2000; Van den
Bosch et al., 2000; Chaudhari et al., 2001; Ellis and Krueger,
2001; Ogilvie et al., 2001). More data on the role of CD11a
blockade with regards to infections are accumulating. Of
interest is a recently published pooled analysis of phase-III
clinical trials, indicating that the incidence and severity of
infections in efalizumab- and placebo-treated patients were
similar during the controlled portion of trials, and the
incidence of infection did not increase with extended therapy
up to 27 months (Langley et al., 2005).
This study also demonstrates that the impact of immune
modulators may be different in humans from what is
predicted by gene-knockout or therapeutic surrogate animal
models of immunity and disease. Although operationally and
technically extremely challenging, more human immuniza-
tion data will further help us understand the entire impact of
biological and non-biological immunotherapy in humans
(Derkx et al., 1993; Bohmig et al., 1994; Elliott et al.,
1994a, b, 1997; van Dullemen et al., 1995; Moreland et al.,
1996, 1997; Dengler et al., 1998; Abrams et al., 1999; Mease
et al., 2000; Van den Bosch et al., 2000; Chaudhari et al.,
2001; Ellis and Krueger, 2001; Ogilvie et al., 2001; Whitten
and Oldstone, 2001; Zinkernagel et al., 2001; Langley et al.,
2005).
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Figure 4. Response to tetanus booster vaccine. (a) GMs of anti-tetanus toxoid
(IgG titers (IU ml1) before and 4 weeks after booster vaccination on day 35
during treatment period, with 95% CIs shown at each data point.
(b) Percentage of patients with anti-tetanus toxoid IgG X0.5 IU ml1
(with 95% CIs based on the binomial distribution) at each data point.
Positive anti-tetanus antibody levels defined as X0.5 IU ml1.
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with positive antibody responses to one or more pneumococcal antigens
compared with the baseline 4 weeks after Pneumovax 23 vaccination
administered on FU day 42. FU, follow-up.
120 C. albicans
89
63
77
91
40
46
63
36
26
20
41
30 31
38
n=28 n=16 n=22 n=27 n=15 n=22 n=27 n=13 n=21
n=28 n=16 n=22 n=27 n=15 n=22 n=27 n=13 n=21
78
69
76
67
100
80
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
po
sit
ive
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
po
sit
ive
60
40
Screening
Tetanus
Treatment day 35 FU day 77
Screening Treatment day 35 FU day 77
Group A
Group B
Group C
20
0
100
80
60
40
20
0
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(b) Response to intracutaneous tetanus toxoid antigen.
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MATERIALS AND METHODS
Study design
Genentech Protocol ACD2244g, Protocol Amendment I, and the
Subject Informed Consent for this single-site study were submitted
to, reviewed by, and approved by IRB Services (Aurora, ON,
Canada). All subsequent amendments and versions of the patient
consent were similarly Institutional Review Board-approved for this
study. All patients enrolled in ACD2244g gave consent for
participation in the study via the Institutional Review Board-
approved consent form prior to commencement of any study
procedures. This study is registered at clinicaltrials.gov. Its unique
identifier/registration number is NCT00382512. The study was
conducted according to the Declaration of Helsinki Principles.
Ninety-eight patients were screened for this study, and 66 with
moderate plaque psoriasis (8–15% affected body surface area,
n¼ 66) between 18–65 years old, with no evidence of infection,
malignancy, pregnancy, and history of hypersensitivity reaction to
any of the administered vaccinations, were randomized and enrolled
in the study. Of the 66 patients randomized, four patients
discontinued study drug during the treatment period: 1 (3.6%) in
group A, 2 (12.5%) in group B, and 1 (4.5%) in group C. One patient
in group B (6.3%) discontinued the drug during the follow-up period
(Figure 1). The eligible patients were randomized using a computer-
generated schedule in blocks of six individuals into three experi-
mental groups (A–C), and allotted the next sequential number on the
randomization schedule, which was predetermined and associated
with a specific treatment. All patients did not receive systemic or
ultraviolet therapy for at least 4 weeks prior to screening day. Topical
treatment was allowed on untested skin. McDougall Scientific
Limited (Toronto, ON, Canada) was responsible for generation of the
randomization schedule. Allied Clinical Research was responsible
for conduct of the study. This was a single-blind study. A trained
research-team member administered all doses of the study drug.
Patients were analyzed according to their actual study treatments
and fX174 immunizations.
Groups A and B received 1 mg kg1 efalizumab treatment weekly
for 12 weeks and were followed thereafter for an additional 14
weeks (‘‘wash out’’). Group C received placebo for 12 weeks and
was followed for an additional 14 weeks. The main study objective
was to measure primary and secondary immune responses to the
experimental antigen fX174 administered during and after efalizu-
mab treatment (group A), versus fX174 administered only after
efalizumab treatment (group B). The study also had the secondary
objective of measuring immune responses to several unrelated
protein or polysaccharide antigens using two parenteral antigens
(tetanus toxoid and pneumococcal vaccine) given systemically and
two skin test antigens (C. albicans and tetanus toxoid).
All patients were monitored for safety through the 14-week follow-
up period. The Psoriasis Area and Severity Index scores (efficacy) were
not measured in this study. A placebo group (group C) was included to
establish baseline immune responses in psoriasis patients (study
design; Figure 2a). The determination of sample size was based on a
non-inferiority test using the hypothesis that the mean anti-fX174
antibody concentration of each of the efalizumab groups would be no
less than two SDs below the mean for the placebo group.
Binding of efalizumab treatment to CD11a on B cells and T cells
was assessed by flow cytometry using mAb MHM24 (Dako
Corporation, Carpinteria, CA), which binds to the same epitope on
CD11a as efalizumab. Modulation (downregulation) of CD11a
expression on lymphocytes was determined using mAb HI111 (BD
Pharmingen, San Diego, CA), which binds to an epitope on CD11a
different from efalizumab.
Immunization with /X174
fX174 (1 1011 plaque-forming units per ml) or vehicle was
administered as an intravenous bolus at a dose of 0.02 ml kg1 body
weight (2 109 plaque-forming units per kg) on day 35, day 63, and
on follow-up days 42 and 70. Blood samples to detect circulating
fX174 were collected 15 minutes after phage injection. Sera for
antibody determination were obtained 2 and 4 weeks after each
administration of fX174 or vehicle. Antibody titers are expressed as
the rate of phage inactivation, or Kv, as described previously (Ochs
et al., 1971). The phage-neutralizing antibody resistant to treatment
with 2-mercaptoethanol is considered as IgG (Ochs et al., 1971;
Pyun et al., 1989). The mean percent IgG and CI were calculated on
the arcs in transformed values and then transformed back to the
percent scale for reporting.
Immunization with tetanus toxoid
All patients received an intramuscular tetanus booster vaccination
(Td absorbedTM; Aventis Pasteur Limited, Toronto, ON, Canada) on
day 35. Antibody levels were measured by IBT Reference Laboratory
(Lenexa, KA) using an enzyme immunoassay that has a dynamic
range of 0.01 to 18.5 IU ml1 IgG and a detection limit of
0.01 IU ml1. Anti-tetanus toxoid IgG antibody levels X0.5 IU ml1
were defined as positive and protective. An increase in anti-tetanus
toxoid IgGX0.5 IU ml1 above baseline is classified as a ‘‘clinically
meaningful’’ increase.
Immunization with pneumococcal polysaccharides
A pneumococcal vaccine containing 23 pneumococcal polysac-
charide types (Pneumovax 23 pneumococcal vaccine polyvalent;
Merck & Co. Inc., Whitehouse Station, NJ) was used (Figure 2).
A fluoroimmunoassay was developed and performed by IBT
Reference Laboratory. Serum IgG antibody concentrations against
12 of the 23 pneumococcal antigens contained in the vaccine were
determined (US nomenclature strains 1, 3, 4, 8, 9, 12, 14, 19, 23, 26,
51, and 56). The detection limit for antibodies against each strain
was 1.4mg ml1. As many patients in this study had measurable anti-
pneumococcal antibodies against some strains (typically 1–3) at
baseline, antibody responses to each of the 12 antigens were
determined after immunization and compared with the baseline; the
difference in the number of antigens recognized is shown for all
pooled efalizumab patients and compared with the placebo group.
Median changes in individual antibody titers were also determined.
Skin testing for delayed-type hypersensitivity
Recall antigens C. albicans (Candin; Allermed Laboratories Inc., San
Diego, CA) and tetanus toxoid (1:10 diluted; Aventis Pasteur Inc.,
Swiftwater, PA) were administered intracutaneously on the patient’s
forearm and observed 48–72 hours after application. A positive
reaction was defined as induration and erythema X2 mm.
Statistical analysis and evaluations
Data management and statistical analysis activities for the study
were conducted under the overall responsibility of Janet McDougall
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at McDougall Scientific Ltd. The analysis intent-to-treat population
for vaccination endpoints consisted of all patients who were
randomized into the study and had received any amount of the
study drug. Endpoints included quantification of the antibody
responses to fX174 (Kv) at various time points, isotype switch
(%IgG) following each booster immunization with fX174, anti-
tetanus toxoid antibody titers (IgG), anti-pneumococcal antibody
titers to 12 serotypes, and intracutaneous skin test reactions to
tetanus and Candida antigens (delayed-type hypersensitivity). The
GM of the anti-fX174 antibody titers, expressed as Kv and
determined 2 weeks after immunizations 3 and 4 for group A and
immunizations 1 and 2 for group B, were compared with the GM
K-values observed in group C. A one-way analysis of variance was
performed at each time point using a model with treatment group as
the independent factor and Dunnett’s adjustment to construct
simultaneous 95% CIs for the difference between mean log10 anti-
fX174 antibody Kv for each efalizumab-treated group and the
placebo-treated group.
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